Alprazolam
1Provenance card
the boundary, as counts
Sources
4515 with DOI
16 strong · 23 moderate · 6 weak
Compilations
22026-04-20T21:38:05.185Z
pipeline-v5 · prompt hash not recorded — run predates 2026-09 · 1 other run
Decisions
66last ruled 2026-06-04
1 awaiting a ruling
Issued documents
42026-10-19T20:30:34.535Z
notice · info card · emergency
Searches
00 with no results
queries and counts on the build
Claims checked
10380 supported
80 supported · 23 not
Correspondence
0received
consent field ships in Phase 4
Edges
309
derivations recorded for this entity
Complete over 45 sources, 2 compilations, and 66 decisions.Not here: the private journal (never); 1 proposal awaiting a ruling (listed as pending only).Working material — drafts, discards, unsupported claims — is listed below and readable on the working page.Cite: psychedex.org/substances/alprazolam/archive
Timeline
what happened, newest first — claims, searches and artifacts stay inside Build
- 2026-10-19issueIssued info_card
- 2026-10-02srcPotential role for histone deacetylation in chronic diazepam-induced downregulation of alpha1-GABAA receptor subunit expression.
- 2026-10-02srcThe hippocampus under influence: structural effects of synthetic and natural psychotropic medications.
- 2026-10-02srcRationalizing the binding and alpha subtype selectivity of synthesized imidazodiazepines and benzodiazepines at GABAA receptors by using molecular docking studies.
- 2026-10-02srcEfficacy of CBT for benzodiazepine discontinuation in patients with panic disorder: Further evaluation.
- 2026-10-02srcTolerance and dependence following chronic alprazolam treatment in rhesus monkeys: Role of GABAA receptor subtypes.
- 2026-10-02srcBenzodiazepine exposure induces transcriptional down-regulation of GABAA receptor alpha1 subunit gene via L-type voltage-gated calcium channel activation.
- 2026-10-02srcAlprazolam misuse: Analysis of French Addictovigilance Network data from 2011 to 2020.
- 2026-10-02srcUtility of CYP3A4 and PXR-CAR-CYP3A4/3A7 Transgenic Mouse Models To Assess the Magnitude of CYP3A4 Mediated Drug-Drug Interactions.
- 2026-10-02srcAGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011.
- 2026-10-02srcThe efficacy and safety of alprazolam versus other benzodiazepines in the treatment of panic disorder.
- 2026-10-02srcThe Effect of Chronic Alprazolam Intake on Memory, Attention, and Psychomotor Performance in Healthy Human Male Volunteers.
- 2026-10-02srcThe role of alprazolam for the treatment of panic disorder in Australia.
- 2026-10-02srcBenzodiazepines: a major component in unintentional prescription drug overdoses with opioid analgesics.
- 2026-10-02srcAcute fatal posthypoxic leukoencephalopathy following benzodiazepine overdose: a case report.
- 2026-10-02srcImpaired Cognitive Function and Hippocampal Changes Following Chronic Diazepam Treatment in Middle-Aged Mice.
- 2026-10-02srcMolecular and neurochemical evaluation of the effects of etizolam on GABAA receptors under normal and stress conditions.
- 2026-10-02srcPharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.
- 2026-10-02srcEffects of the antifungal agents on oxidative drug metabolism: clinical relevance.
- 2026-10-02srcEffect of alosetron on the pharmacokinetics of alprazolam.
- 2026-10-02srcPharmacotherapy of generalized anxiety disorder.
- 2026-10-02srcClinical pharmacology, clinical efficacy, and behavioral toxicity of alprazolam: a review of the literature.
- 2026-10-02srcRequirement of alpha5-GABAA receptors for the development of tolerance to the sedative action of diazepam in mice.
- 2026-10-02srcSpontaneous withdrawal from the triazolobenzodiazepine alprazolam increases cortical corticotropin-releasing factor mRNA expression.
- 2026-10-02srcIs benzodiazepine use a risk factor for cognitive decline and dementia? A literature review of epidemiological studies.
- 2026-10-02srcA method for determining the magnitude of change across different cognitive functions: effects of acute alprazolam.
- 2026-10-02srcChronic benzodiazepine administration: from the patient to the gene.
- 2026-10-02srcCognitive, psychomotor and actual driving performance in healthy volunteers after immediate and extended release formulations of alprazolam 1 mg.
- 2026-10-02srcAn overdose death involving the insufflation of extended-release oxymorphone tablets.
- 2026-10-02srcChronic use of benzodiazepines and psychomotor and cognitive test performance.
- 2026-10-02srcPharmacokinetics and pharmacodynamics of alprazolam after oral and IV administration.
- 2026-10-02srcStudies with [11C]alprazolam: an agonist for the benzodiazepine receptor.
- 2026-10-02srcPrecipitated withdrawal in squirrel monkeys after repeated daily oral administration of alprazolam, diazepam, flunitrazepam or oxazepam.
- 2026-10-02srcAlprazolam absorption kinetics affects abuse liability.
- 2026-10-02srcA single amino acid of the human gamma-aminobutyric acid type A receptor gamma2 subunit determines benzodiazepine efficacy.
- 2026-10-02srcTreatment of alprazolam withdrawal with chlordiazepoxide substitution and taper.
- 2026-10-02srcDouble-blind study of alprazolam, diazepam, clonidine, and placebo in the alcohol withdrawal syndrome.
- 2026-10-02srcAdverse behavioral events reported in patients taking alprazolam and other benzodiazepines.
- 2026-10-02srcClinical pharmacokinetics of alprazolam. Therapeutic implications.
- 2026-10-02srcEffect of alprazolam on opiate withdrawal: a combined behavioural and microdialysis study.
- 2026-10-02srcPharmacokinetics and psychomotor performance of alprazolam: concentration-effect relationship.
- 2026-10-02srcSequestration of gamma-aminobutyric acidA receptors on clathrin-coated vesicles during chronic benzodiazepine administration in vivo.
- 2026-10-02srcPanic disorder: long-term pharmacotherapy and discontinuation.
- 2026-10-02srcAlprazolam Physical Properties and Chemical Identity
- 2026-10-02srcAlprazolam (PIM 199) - INCHEM Toxicological Monograph
- 2026-10-02srcAlprazolam - History and Legal Status
- 2026-09-27runbrief run
- 2026-09-27revisionr1.a1
- 2026-09-04issueIssued emergency
- 2026-09-04issueIssued info_card
- 2026-09-04issueIssued notice
- 2026-07-03proposaldependence · taper
- 2026-06-04proposal37 value proposals approved togetherone review action inferred from a shared reviewer and instant — the graph records one activity per proposal
- 2026-06-04publicationPublication — backfill
- 2026-04-20proposaldosage · sublingual
- 2026-04-20proposaldosage · oral
- 2026-04-20proposaltolerance
- 2026-04-20proposalwithdrawal
- 2026-04-20proposaldependence · full
- 2026-04-20proposaltoxicity
- 2026-04-20proposaldose_tier · light
- 2026-04-20proposaldose_tier · threshold
- 2026-04-20proposalduration · sublingual · total
- 2026-04-20proposalduration · sublingual · onset
- 2026-04-20proposalduration · oral · aftereffects
- 2026-04-20proposalduration · oral · total
- 2026-04-20proposalduration · oral · offset
- 2026-04-20proposalduration · oral · peak
- 2026-04-20proposalduration · oral · come_up
- 2026-04-20proposalduration · oral · onset
- 2026-04-20proposaltimeline · oral · afterglow
- 2026-04-20proposaltimeline · oral · resolution
- 2026-04-20proposaltimeline · oral · plateau
- 2026-04-20proposaltimeline · oral · peak
- 2026-04-20proposaltimeline · oral · come_up
- 2026-04-20proposaltimeline · oral · onset
- 2026-04-20proposaldose_tier · heavy
- 2026-04-20proposaldose_tier · strong
- 2026-04-20proposaldose_tier · common
- 2026-04-20revisionRevision 1
- 2026-04-20genGeneration — pipeline-v5 · with 3 morepipeline-v5
- 2026-04-20rungeneration run
- 2026-04-20rungeneration run
The same entries, as forms: six forms.